Overview
The Teal Wand changes how an eligible, average-risk person may collect a vaginal specimen, not what cervical screening must accomplish. The series moves from ACS eligibility and intervals to FDA’s prescription, Class II, assay-specific scope, then follows collection, laboratory testing, evidence, risks, and follow-up. It finds high agreement in the tested cobas HPV pathway, while leaving long-term outcomes, routine follow-up, other assays, and higher-risk populations unresolved.
Learning outcomes
- The Teal Wand changes the collection setting, not the full cervical-screening pathway.
- FDA’s scope is prescription home collection and transport of vaginal specimens for a validated HPV assay.
- The tested cobas HPV pathway showed high agreement, but the evidence does not establish universal performance or cancer outcomes.
- A negative result still requires scheduled screening; an abnormal result can require cervical sampling and follow-up.
Keywords
Preview every chapter · Unlock full text, audio, and video from chapter 4
PlansFAQ
Does the Teal Wand replace cervical screening?
No. The Teal Wand changes the initial collection route, but screening still requires an authorized assay, result interpretation, repeat screening, and provider follow-up when indicated.
Who may consider self-collected HPV testing?
ACS describes it as an option for average-risk, asymptomatic people with a cervix when a provider orders an authorized test and device. Symptoms or higher-risk history may require a different plan.
What did the Teal Wand FDA decision authorize?
It classified the Teal Wand as a prescription-use Class II device for home or private collection and transport of vaginal specimens for a validated FDA-approved HPV molecular assay. It did not authorize universal assay, population, or pathway replacement.
How strong is the evidence for Teal Wand testing?
In 582 valid paired specimens, self-collected and clinician-collected results showed 95.2% positive percent agreement and 90.0% negative percent agreement in the cobas HPV workflow. Those figures do not establish cancer prevention, routine follow-up, or universal performance.